Elevra Lithium Announces NAL Expansion Pre-Feasibility Study
BRISBANE, Australia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra" or "Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce the results of a Pre-Feasibility Study ("PFS") for the staged North American Lithium ("NAL") Brownfield Expansion in Québec. The PFS confirms the NAL Expansion as a high-value growth project that is expected to significantly increase annual spodumene concentrate production while reducing unit operating costs and generating attractive returns on capital invested.
Covered in this story
What has happened since
- Elevance Health is up 9.5% since this was published, 42 days ago.
- Provident Financial Services Inc is down 3.8% since this was published, 42 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Elevance Health
- Guggenheim: $421 → $460 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ELV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Elevance Health →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.